Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 13, 2023 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference

REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
April 04, 2023 17:15 ET | Source: The Rosen Law Firm PA

ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT

NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...
March 07, 2023 16:02 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

REDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
March 01, 2023 16:17 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Announces Commencement of Public Offering of Common Stock

REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
February 27, 2023 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress

Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation Additional data releases for RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) expected in 2023 RMC-9805...
February 21, 2023 16:05 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023

REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
February 02, 2023 07:00 ET | Source: Revolution Medicines, Inc.

Revolution Medicines to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
January 24, 2023 11:30 ET | Source: Access Information Management Shared Services, LLC

Access Recognized in Two Categories by Inc.’s Prestigious Inaugural Power Partner Awards

WOBURN, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Access, the world’s largest privately-held integrated information management services provider, today announced that it has been recognized by Inc....
January 03, 2023 09:00 ET | Source: leon-nanodrugs GmbH

LEON successfully completes development of its innovative reactor for more efficient production of lipid nanoparticles

LEON achieved superior accuracy in development of its proprietary reactor, facilitating exceptional inter-device reproducibility of particle size and distribution, and thus seamless process transfer,...
December 19, 2022 08:31 ET | Source: MamaMancini's Holdings, Inc.

MamaMancini’s Appoints Meghan Henson to Board of Directors

Seasoned Human Resources Executive Brings 20+ Years of Experience to the Board of Directors EAST RUTHERFORD, NJ, Dec. 19, 2022 (GLOBE NEWSWIRE) -- MamaMancini's Holdings, Inc. (NASDAQ: MMMB), a...